SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

Clinical trial NCT02581787 · COMPLETED

Trial details

NCT number: NCT02581787
Sponsor: Maximilian Diehn
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Stage IA Non-Small Cell Lung Carcinoma Stage IB Non-Small Cell Lung Carcinoma

Start date: 2016-08-01
Primary completion: 2023-03-02
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.